Blood Conservation in Cardiac Surgery

This study has been terminated.
(Study is terminated at HackensackUMC - PI left and went to UMDNJ- Robert Wood Johnson Medical Center)
Sponsor:
Collaborator:
University of Medicine and Dentistry New Jersey
Information provided by (Responsible Party):
Hackensack University Medical Center
ClinicalTrials.gov Identifier:
NCT01463345
First received: October 27, 2011
Last updated: May 20, 2013
Last verified: May 2013

October 27, 2011
May 20, 2013
November 2011
November 2013   (final data collection date for primary outcome measure)
Safety of the lower hemoglobin transfusion trigger of 7.5 g/dl against the higher hemoglobin transfusion trigger of 9.0 g/dl. [ Time Frame: The assessment will last untill day 4 post surgery ] [ Designated as safety issue: Yes ]
This outcome measure is a simultaneous assessment of the multiple end points duration of pressor use, symptomatic anemia, anemia-associated hypotension within 48 hours post surgery and Hgb recovery by day 4 post-surgery.
Same as current
Complete list of historical versions of study NCT01463345 on ClinicalTrials.gov Archive Site
Rate of incidence of transfusion related complications between the two randomizations arms. [ Time Frame: This will be compared during the hospital stay, untill 30 days after discharge. ] [ Designated as safety issue: Yes ]
The comparison will be based on a composite end point consisting of transfusion related lung injury (TRALI) that is ARDS, ventilator time>24 hours, pneumonia; stroke (permanent/transient); MI and renal failure.
Same as current
Not Provided
Not Provided
 
Blood Conservation in Cardiac Surgery
Blood Conservation in Cardiac Surgery

The objective of the study is to examine the safety of two different hemoglobin (Hgb)-based transfusion triggers in patients post cardiac surgery.

Nearly 20% of blood transfusions in the United States are given to in patients undergoing cardiac surgery. Despite the many blood conservation techniques that are available, safe, and efficacious for patients, many of these operations continue to be associated with significant amounts of blood usage. We believe that transfusion protocols which employ specific guidelines for transfusion can decrease blood product usage and improve outcomes for patients undergoing cardiac surgery. Our goal is to demonstrate that a carefully chosen trigger can achieve better outcomes.

Our hypothesis is that a transfusion trigger of Hgb 7.5 g/dl will lead to decreased utilization of blood transfusions and will have many positive effects on the patients post cardiac surgery in addition to substantial cost savings. We will use an evidence based approach to observe the relative safety of a conservative transfusion trigger (7.5 g/dl) as compared to a more liberal trigger (9.0 g/dl). We will also study the effect of blood conservation on the incidence of transfusion-related complications such as transfusion related lung injury (TRALI) and infectious complications as well as length of hospital stay, cost and ventilator time.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
  • Transfusion Reactions
  • Post Cardiac Surgery
  • Other: Blood transfusion
    Conservative transfusion arm: Subjects randomized to the conservative transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures < 7.5 g/dl. Blood products should be given to maintain Hgb levels >7.5 g/dl.
  • Other: Blood transfusion
    Liberal transfusion arm: Subjects randomized to the liberal transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures < 9.0 g/dl. Blood products should be given to maintain Hgb levels > 9.0 g/dl.
  • Experimental: Conservative Transfusion Arm
    Subjects in the conservative transfusion arm will receive transfusion only when their hemoglobin levels reach 7.5 g/dl.
    Intervention: Other: Blood transfusion
  • Active Comparator: Liberal Transfusion Arm
    Subjects in the liberal transfusion arm will receive transfusion only when their hemoglobin levels reach 9.0 g/dl.
    Intervention: Other: Blood transfusion
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
900
November 2013
November 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

Subjects who meet all of the following criteria will be considered for inclusion in this study:

  1. Subjects scheduled to undergo any of the following cardiac surgeries as part of their routine medical care:

    • CABG
    • AVR
    • MVR
    • MV Repair
    • CABG/AVR
    • CABG/MVR
    • CABG/MV Repair
    • Thoracic Aneurysm Repair ± any concomitant cardiac procedure (valve, CABG, etc.)
  2. Subjects must be > 18 years of age
  3. No prior history of cardiac surgery.
  4. Able and willing to give informed consent

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from participation in this study:

  1. Prior history of cardiac surgery
  2. Patients who do not have sufficient time prior to surgery to give proper informed consent (i.e.: immediate, emergency surgery)
  3. Patients who are younger than 18 years of age
  4. Prior history of

    • bleeding disorders
    • symptomatic anemia (i.e. persistent tachycardia, orthostatic hypotension, persistent pressor requirement)
    • hereditary/acquired coagulopathy
    • platelet defects (e.g.: disseminated intravascular coagulation (DIC), hemophilia, Henoch-Schönlein purpura, hereditary hemorrhagic telangiectasia, thrombocytopenia (ITP, TTP), thrombophilia, Von Willebrand's disease)
  5. History of leukemia or any other blood related malignancy
  6. History of liver failure
  7. Current, or history of, pre-existing medical condition other than current cardiac condition, which in the opinion of the investigator, would place the subject at risk or have the potential to confound interpretation of the study results
  8. Participation in another clinical trial
  9. Lack of capacity to give informed consent.
Both
21 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01463345
Pro00001949
Yes
Hackensack University Medical Center
Hackensack University Medical Center
University of Medicine and Dentistry New Jersey
Principal Investigator: Leonard Lee, M.D. Dr Lee is leaving Hackensack University Medical Center on June 30th, 2012. Effective July 1st, 2012 he will assume his new role as the Chief of Cardiothoracic Surgery Division at the University OF Medicine & Dentistry OFNew Jersey-Robert Wood Johnson
Hackensack University Medical Center
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP